Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Merck & Co (NY:MRK)

80.93 -1.46 (-1.77%)
Official Closing Price Updated: 5:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
87 88 Next >
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
MERCK & CO. INC. (NYSE:MRK) - A Reliable Dividend Stock with Strong Fundamentals
MERCK & CO. (NYSE:MRK) offers a strong 4.2% dividend yield, consistent growth, and solid financial health, making it a top pick for dividend investors. 
Via Chartmill
"If Walmart Is Under Pressure to Raise Prices, It's Going to Have Broader Effects on the Economy."
Via The Motley Fool
Topics Earnings Economy World Trade
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics
The companies are duking it out for the best treatment for head-and-neck cancer. One clearly has the edge. 
Via Investor's Business Daily
3 Dow Jones Stocks on Our Watchlist
The Dow Jones (^DJI) includes some of the most reliable stocks in the market, and while not all are equal, a few continue to shine. These companies are leveraging their strengths to maintain leadership... 
Via StockStory
Topics Stocks
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Moderna Stock Looks Ripe for a Short Squeeze
Moderna stock has made single-digit gains in the last month, and high short interest suggests that any bullish news could cause a short squeeze 
Via MarketBeat
Topics Government
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Via The Motley Fool
Topics Economy Law Enforcement
Spotlight on Merck & Co: Analyzing the Surge in Options Activity
Via Benzinga
MERCK & CO. INC. (NYSE:MRK) - A Strong Value Candidate in Pharmaceuticals
MERCK & CO. (NYSE:MRK) offers strong value with a low P/E ratio, high profitability, and a reliable dividend. A solid pick for value investors in the pharmaceutical sector. 
Via Chartmill
Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money
Via The Motley Fool
Topics Artificial Intelligence
Decoding Merck & Co's Options Activity: What's the Big Picture?
Via Benzinga
Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda
Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors. 
Via Benzinga
Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo
Immutep's efti combo with Keytruda and chemo shows a 60.8% response rate in lung cancer trial, with strong efficacy across PD-L1 expression levels. 
Via Benzinga
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025
For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity. 
Via Benzinga
CMS Expands Medicare Drug Price Talks To Part B Meds In 2026 Shake Up
CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26. 
Via Benzinga
FDA Approves Merck's Kidney Cancer Drug For Rare Type Of Neuroendocrine Tumors
Merck's Welireg wins FDA approval for rare PPGL tumors; Q1 2025 sales reach $137M, marking a 62% year-over-year increase. 
Via Benzinga
3 Absurdly Cheap Stocks Trading Near Their 52-Week Lows
Via The Motley Fool
Topics Artificial Intelligence World Trade
Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards?
Only about 50% of S&P 500 stocks trade above their 200-day average, signaling narrow breadth even as the index rallies 22% since April. 
Via Benzinga
Topics Stocks
Assessing Merck & Co: Insights From 4 Financial Analysts
Via Benzinga
Top S&P500 movers in Tuesday's session
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday. 
Via Chartmill
Stay informed with the top movers within the S&P500 index on Tuesday.
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
These S&P500 stocks are gapping in today's session
Stay tuned for the market movements in the S&P500 index on Tuesday. Check out the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
Market Monitor News May 12 ( NRG Energy, Amazon, Meta Platforms UP - CVS Health DOWN)
Wall Street surges sharply as US-China tariff cuts drive tech stocks higher; pharma sector gains on new Trump drug pricing initiative. 
Via Chartmill
Topics Government World Trade
Dow Jones Adds 1,000 Points, Breaks 200-Day Moving Average For First Time Since April 2 Tariff Shock
The Dow surged 1,100 points after a U.S.-China trade truce, breaking above its 200-day average and fueling hopes of a market rebound — with caveats. 
Via Benzinga
Topics Stocks
Merck, Pfizer, Eli Lilly Stocks Rebound As Trump Targets Drug Costs With New Executive Order
The U.S. President said that Big Pharma would either voluntarily abide by this principle or the federal government will use its power to ensure the U.S. pays the same price as other countries. 
Via Stocktwits
Topics Government
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices. 
Via Investor's Business Daily
Topics Government Stocks
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots
Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space. 
Via Benzinga
Topics Artificial Intelligence
MRK Q1 Earnings Call: Pipeline Expansion, Tariff Pressures, and Portfolio Diversification
Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 1.6% year on year to $15.53 billion. The company expects the... 
Via StockStory
Topics Economy World Trade
Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket
What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription... 
Via Benzinga
Topics Government
< Previous 1 2 3 4 5 6 7 8 9
...
87 88 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.